Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Technology ID
TAB-4164

Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers

E-Numbers
E-001-2016-0
Lead Inventors
Kochenderfer, James
Applications
Therapeutics
Therapeutic Areas
Oncology
Development Stages
Pre-clinical (in vivo)
Lead IC
NCI
ICs
NCI

Chimeric antigen receptors (CARs) are hybrid proteins that consist of two major components: a targeting domain and a signaling domain.  The targeting domain allows T cells which express the CAR to selectively recognize and bind to diseased cells that express a particular protein.  Once the diseased cell is bound by the targeting domain of the CAR, the signaling domain of the CAR activates the T cell, thereby allowing it to kill the diseased cell.  This is a promising new therapeutic approach known as adoptive cell therapy (ACT).

Researchers at the NCI Experimental Transplantation and Immunology Branch developed a CAR that recognizes human tumor necrosis factor receptor superfamily member 8 (TNFRSF8, also known as CD30). The expression of CD30 is deregulated in a variety of human cancers, including many lymphomas.  By creating a CAR that recognizes CD30, it may be possible to treat these cancers using adoptive cell therapy.

Competitive Advantages:

  • Human components are less likely to cause adverse or neutralizing immune response in patients
  • Targeted therapies decrease non-specific killing of healthy cells and tissues, resulting in fewer off-target side-effects and healthier patients

Commercial Applications:

  • Treatment of human cancers associated with expression of CD30 or variants thereof
  • Specific cancers include: Non-Hodgkins Lymphomas, Hodgkin's Lymphomas, several solid malignancies

Request More Info

Licensing Contacts
Burke, Andrew
burkear@mail.nih.gov

Patents

  • US
    Provisional (PRV) 62/241,896
    Filed on 2015-10-15
    Status: Abandoned
  • Patent Cooperation Treaty
    (PCT) PCT/US2016/056262
    Filed on 2016-10-10
    Status: Expired
  • Australia
    National Stage 2016338747
    Filed on 2016-10-10
    Status: Abandoned
  • Brazil
    National Stage BR112018006995-7
    Filed on 2018-04-06
    Status: Abandoned
  • Canada
    National Stage 3002000
    Filed on 2016-10-10
    Status: Abandoned
  • China
    National Stage 201680059341.3
    Filed on 2016-10-10
    Status: Abandoned
  • European Patent
    National Stage 16784695.5
    Filed on 2016-10-10
    Status: Issued
  • India
    National Stage 201847016354
    Filed on 2016-10-10
    Status: Abandoned
  • Japan
    National Stage 2018-518999
    Filed on 2018-04-12
    Status: Abandoned
  • Mexico
    National Stage MX/a/2018/004503
    Filed on 2016-10-10
    Status: Abandoned
  • US Patent 10,815,301
    Filed on 2018-04-09
    Status: Issued
  • Israel
    Ordinary Patent (ORD) 258527
    Filed on 2018-04-08
    Status: Abandoned
  • South Korea
    National Stage 10-2018-7013573
    Filed on 2018-05-14
    Status: Abandoned
  • Saudi Arabia
    Ordinary Patent (ORD) 518391355
    Filed on 2018-04-12
    Status: Abandoned
  • Germany
    European patent (EP) 16784695.5
    Filed on 2016-10-10
    Status: Abandoned
  • France
    European patent (EP) 16784695.5
    Filed on 2016-10-10
    Status: Abandoned
  • United Kingdom
    European patent (EP) 16784695.5
    Filed on 2016-10-10
    Status: Abandoned

Collaborations

  • Licensing
  • Collaboration
Date Published